Pravin U. Dugel, MD, becomes president, CEO of Ocular Therapeutix
Click Here to Manage Email Alerts
Key takeaways:
- Antony Mattessich has stepped down as president and CEO.
- Pravin U. Dugel, MD, will continue as director and executive chairman.
Ocular Therapeutix announced changes to its executive team, with Pravin U. Dugel, MD, assuming the roles of president and CEO and Antony Mattessich stepping down from these positions, effective immediately.
Dugel will continue in his current roles of director and executive chairman, according to a press release.
“On behalf of the board of directors and employees of Ocular, I want to wholeheartedly express Ocular’s utmost gratitude for Antony's many years of exceptional service and unwavering commitment to the company,” Dugel said in the release. “His passion and dedication [have] guided Ocular for years, enabling the formation of a high-quality organization and the development of our innovative retinal disease pipeline, led by Axpaxli. I believe Axpaxli has the potential to dramatically change the treatment paradigm for retinal disease and look forward to advancing the development of this innovative product candidate in 2024 and beyond.”
Dugel previously held leadership positions at Iveric Bio, Retinal Consultants of Arizona and the Retinal Research Institute, and USC Eye Institute.
Read more about
Click Here to Manage Email Alerts